Does DOCETAXEL\DOCETAXEL ANHYDROUS Cause Malignant neoplasm progression? 126 Reports in FDA Database
Prostate Health & Male Vitality — Naturally
ProstaVive: better flow, better sleep, better energy. 180-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 126 reports of Malignant neoplasm progression have been filed in association with DOCETAXEL\DOCETAXEL ANHYDROUS. This represents 3.3% of all adverse event reports for DOCETAXEL\DOCETAXEL ANHYDROUS.
126
Reports of Malignant neoplasm progression with DOCETAXEL\DOCETAXEL ANHYDROUS
3.3%
of all DOCETAXEL\DOCETAXEL ANHYDROUS reports
39
Deaths
16
Hospitalizations
How Dangerous Is Malignant neoplasm progression From DOCETAXEL\DOCETAXEL ANHYDROUS?
Of the 126 reports, 39 (31.0%) resulted in death, 16 (12.7%) required hospitalization, and 3 (2.4%) were considered life-threatening.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for DOCETAXEL\DOCETAXEL ANHYDROUS. However, 126 reports have been filed with the FAERS database.
What Other Side Effects Does DOCETAXEL\DOCETAXEL ANHYDROUS Cause?
Diarrhoea (409)
Myelosuppression (404)
Disease progression (289)
Off label use (281)
Nausea (279)
Neutropenia (250)
Fatigue (236)
Pyrexia (221)
Vomiting (216)
Asthenia (190)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
Which DOCETAXEL\DOCETAXEL ANHYDROUS Alternatives Have Lower Malignant neoplasm progression Risk?
DOCETAXEL\DOCETAXEL ANHYDROUS vs DOCONEXENT
DOCETAXEL\DOCETAXEL ANHYDROUS vs DOCONEXENT\ICOSAPENT
DOCETAXEL\DOCETAXEL ANHYDROUS vs DOCONEXENT\ICOSAPENT\PHOSPHATIDYL SERINE
DOCETAXEL\DOCETAXEL ANHYDROUS vs DOCOSANOL
DOCETAXEL\DOCETAXEL ANHYDROUS vs DOCUSATE